The selective alpha isoform inhibitor alpelisib (BYL719) was the first oral PI3Ki developed and was recently approved for the treatment of advanced PIK3CA-mutated ER+/HER2– BC progressing on previous ET (Table 2, Figure 4) [85]. Here, PIK3CA is linked to breast cancer.